Small fibre neuropathy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:29:43 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Small fibre neuropathy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effect of Human Normal Immunoglobulin and Sodium Chloride on Pain Relief in Patients with Idiopathic Painful Sensory Neuropathy https://clinicaltrials.eu/trial/study-on-the-effect-of-human-normal-immunoglobulin-and-sodium-chloride-on-pain-relief-in-patients-with-idiopathic-painful-sensory-neuropathy/ Wed, 29 Apr 2026 14:25:01 +0000 https://clinicaltrials.eu/trial/study-on-the-effect-of-human-normal-immunoglobulin-and-sodium-chloride-on-pain-relief-in-patients-with-idiopathic-painful-sensory-neuropathy/ This clinical trial is focused on studying the effects of a treatment for a condition known as idiopathic painful small fiber neuropathy or sensory neuronopathy. These are conditions that cause pain due to damage to the small nerve fibers, which can affect sensation. The treatment being tested is called Privigen, which is a solution containing human normal immunoglobulin. This is a type of protein that is usually found in the blood and helps the immune system fight infections. The study will also use a placebo for comparison purposes.

The purpose of the study is to investigate whether Privigen can help reduce pain in patients with these nerve conditions. Participants in the study will receive the treatment through an intravenous infusion, which means the solution is given directly into a vein. The study will last for several weeks, during which participants will receive the treatment and have their pain levels monitored. The goal is to see if there is a noticeable reduction in pain after receiving the treatment compared to the placebo.

Throughout the study, participants will be asked to report their pain levels and any changes in their quality of life. This information will help researchers understand the effectiveness of Privigen in managing pain associated with these nerve conditions. The study will also monitor for any side effects or adverse events that may occur during the treatment period. By the end of the study, researchers hope to gather enough data to determine if Privigen is a beneficial treatment option for patients with idiopathic painful small fiber neuropathy or sensory neuronopathy.

]]>